english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Building the evidence base

Semaglutide (Wegovy°) for excess body weight: nothing new

Icosapent ethyl (Vazkepa°) in cardiovascular prevention: not acceptable

Metformin during pregnancy: possible risk of malformations

Drugs to avoid in the name of better patient care: 2023 update

Universities challenge the impact factor

Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic

Revolving door between the public and private sectors: conflict of interest

Relugolix + estradiol + norethisterone (Ryeqo°) in uterine fibroids: not acceptable

Setmelanotide (Imcivree°) in certain, very rare, genetic forms of obesity: possibly helpful

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90